Treatment of Klebsiella aerogenes Skin Infections

Initial Antibiotic Selection

The World Health Organization recommends initiating broad-spectrum antibiotic therapy with either a carbapenem (meropenem or imipenem-cilastatin) or a beta-lactam/beta-lactamase inhibitor combination (piperacillin-tazobactam) for skin and soft tissue infections caused by Klebsiella aerogenes, combined with surgical debridement of any necrotic tissue or infected material 1, 2
Carbapenems are the preferred agents for serious K. aerogenes infections, particularly in healthcare settings where extended-spectrum beta-lactamase (ESBL) production is common, with meropenem or imipenem-cilastatin recommended for severe infections 3, 2
Piperacillin-tazobactam is an acceptable alternative for less severe infections or when susceptibility is confirmed, with a dose of 4.5g IV every 6 hours 2

Immediate surgical debridement of necrotic tissue is essential and substantially decreases the risk of invasive infection, with irrigation and debridement being the most important factors in preventing progression to deeper infections 1

The Infectious Diseases Society of America recommends continuing antimicrobial therapy until further debridement is no longer necessary, clinical improvement is evident, and fever has resolved for 48-72 hours, with a minimum of 2 weeks of IV therapy typically required for complicated infections with bacteremia 2
Procalcitonin monitoring may guide antimicrobial discontinuation, and obtaining blood cultures is necessary to rule out concurrent bacteremia 2, 3, 1

K. aerogenes is intrinsically resistant to ampicillin and first/second-generation cephalosporins, and resistance can develop during therapy, particularly with third-generation cephalosporins 3, 2
In settings with high ESBL prevalence, empiric carbapenem coverage is warranted, and immunocompromised or critically ill patients require broad-spectrum coverage and aggressive source control 4, 3, 1

ESBL production is increasingly common among Klebsiella species (e.g., K. pneumoniae, K. aerogenes), conferring resistance to all first‑, second‑, and third‑generation cephalosporins. This epidemiologic observation is supported by surveillance data published in Clinical Infectious Diseases 2011 and 2009, indicating a high and rising prevalence of ESBL‑mediated resistance in clinical isolates. [5][6]

Documented treatment failures occur when ESBL‑producing Klebsiella wound infections are managed with cephalosporins or piperacillin‑tazobactam instead of carbapenems. Retrospective cohort analyses (CID 2009) showed higher rates of clinical non‑response and need for escalation to carbapenem therapy in such cases. 6

Older susceptibility studies from the 1970s–1980s that reported cephalexin activity against Klebsiella are not applicable to current practice, because they predate the widespread emergence of ESBL‑producing strains and therefore underestimate present‑day resistance patterns. This limitation is highlighted in both the 2011 and 2009 CID publications. [5][6]

In neutropenic patients with Klebsiella bacteremia, infections caused by carbapenemase‑producing organisms may require treatment with agents such as colistin or tigecycline rather than any β‑lactam antibiotic. This recommendation is derived from the 2011 CID report on management of multidrug‑resistant Gram‑negative infections in immunocompromised hosts. 5